[Licensing negotiation in progress]
[Invitation for Expression of Interest - Deadline: 9 July 2020]
We are inviting expressions of interest (EoI) for commercializing “Fecal fungome and therapeutic efficacy of fecal microbiota transplantation” technology. The innovation is developed by Professor Ng Siew Chien, Professor of Department of Medicine & Therapeutics of The Chinese University of Hong Kong (CUHK Reference: 18/MED/808).
The Technology
Fecal microbiota transplantation (FMT) is highly effective for the treatment of recurrent Clostridium difficile infection (CDI), and is increasingly being used to treat other intestinal and extra-intestinal diseases. The purpose of this invention is to determine if and how donor and recipient fecal fungomes impact FMT efficacy. The invention demonstrates fecal fungome as one important component influencing FMT efficacy. Occupation of donor-derived fungal taxa in recipient gut fungome, in high proportions, leads to a favourable treatment outcome. Both restoration of gut fungome and bacterial microbiome in FMT recipient are critical in FMT efficacy, while mere reconstitution of the gut bacterial microbiome is associated with disease recurrence.
The applicants have identified Candida albicans as a pivotal fungus compromising FMT efficacy. When recipient is presented with this fungus before FMT and/or is infused with donor feces with presence of Candida albicans , it incurs disease recurrence. Eradication of this fungus in recipients before FMT and use of donor stool without this fungus could restore efficacy of FMT.
This invention encompasses identification and modulation of fecal fungome, particularly Candida albicans, in stool biobank and FMT therapeutics and will have therapeutic and diagnostic applications. . The fecal fungome may be used in screening for donor selection and recipient stratification in personalized FMT practice and for salutary stools as well as its derived products in therapeutic biobanks. Supplementation of specific or modified fungi in donor stool identified by this invention also holds a promising perspective for personalized FMT practice for higher treatment efficacy.
Commercialization
The technology is now available for licensing on an exclusive basis. In order to fully realize the benefit of the technology, we expect substantial investment is necessary to enable further research and development. In addition to the financial commitment, the licensee is expected to have the appropriate expertise as well as plans in marketing and strategizing the end product to ensure successful transfer of the technology to the society. Previous or existing business involvement and experience in this area is a plus.
This invitation of expression of interest is without prejudice. We also stress that this invitation is not a tender, and the University is not bound to accept any offer, or to accept the highest monetary offer, as there are additional considerations (such as the widest possible benefit to the community) that we, as a public institution, will need to take into consideration.
